Ezutromid
Product Sizes
50 mg
£ POA
HY-17614-50MG
5 mg
£ POA
HY-17614-5MG
10 mg
£ POA
HY-17614-10MG
25 mg
£ POA
HY-17614-25MG
100 mg
£ POA
HY-17614-100MG
10mM/1mL
£ POA
HY-17614-10MM
About this Product
- SKU:
- HY-17614
- Additional Names:
- SMT C1100; BMN 195; VOX-C1100
- Application:
- Antibody Microarray
- CAS Number:
- 945531-77-1
- Extra Details:
- Ezutromid (SMT C1100) is a first-in-class; orally active benzoxazole utrophin modulator with an EC50 of 0.91 μM. Ezutromid can be used for the research Duchenne muscular dystrophy (DMD). Ezutromid inhibits CYP1A2 enzymic activity in human liver microsomes (HLM) with an IC50 of 5.4 μM[1][2].
- Molecular Weight:
- 337.39
- Purity:
- 98.94
- References:
- [1]Tinsley JM et al. Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. PLoS One. 2011 May 6;6(5):e19189.|[2]Tinsley J et al. Safety, tolerability, and pharmacokinetics of SMT C1100, a 2-arylbenzoxazole utrophin modulator, following single- and multiple-dose administration to healthy male adult volunteers. J Clin Pharmacol. 2015 Jun;55(6):698-707.|[3]Guiraud S et al. Second-generation compound for the modulation of utrophin in the therapy of DMD. Hum Mol Genet. 2015 Aug 1;24(15):4212-24.|[4]Chancellor DR, et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy. J Med Chem. 2011;54(9):3241-3250.|[5]Chatzopoulou M, et al. Isolation, Structural Identification, Synthesis, and Pharmacological Profiling of 1,2-trans-Dihydro-1,2-diol Metabolites of the Utrophin Modulator Ezutromid. J Med Chem. 2020;63(5):2547-2556.
- Research Area:
- Others
- Shipping Conditions:
- Ambient
- Storage Conditions:
- -20[o]C; 3 years; 4[o]C; 2 years (Powder)
- Type:
- Proteins, Peptides, Small Molecules & Other Biomolecules: Small Molecules
- Pathway:
- Metabolic Enzyme/Protease
